Entasis therapeutics holdings inc. (ETTX)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-43,850

-32,952

-29,923

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

142

164

194

Stock-based compensation expense

2,421

1,201

420

Loss on disposal of property and equipment

-

-282

-

Amortization and accretion of investments

686

21

-

Changes in operating assets and liabilities:
Grants receivable

-474

984

722

Prepaid expenses

3,206

860

-

Other assets

2,711

637

-

Prepaid expenses and other assets

-

-

345

Accounts payable

-30

133

447

Due to related party

-

-

-620

Accrued expenses and other liabilities

2,878

-2,280

3,386

Deferred rent

-175

137

4

Net cash used in operating activities

-44,743

-35,817

-27,159

Cash flows from investing activities:
Purchases of property and equipment

105

370

286

Proceeds from maturities of short-term investments

56,415

-

-

Purchases of short-term investments

44,950

35,721

-

Net cash provided by (used in) investing activities

11,360

-36,091

-286

Cash flows from financing activities:
Proceeds from the sale of shares under common stock purchase agreement, net of issuance costs

155

-

-

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

56,531

Proceeds from exercise of stock options

52

96

56

Proceeds from initial public offering, net of issuance costs paid in the period

-

66,071

-297

Payments of initial public offering costs

150

-

-

Net cash used in financing activities

57

66,167

56,290

Net increase (decrease) in cash and cash equivalents

-33,326

-5,741

28,845

Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable

-

37

190

Commitment shares issued in connection with common stock purchase agreement

642

-

-

Initial public offering costs included in accounts payable and accrued expenses

-

150

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

1,468

Conversion of preferred stock into common stock upon initial public offering

-

104,713

-

Supplemental disclosure of cash flow information:
Cash paid for taxes

677

472

-